255 related articles for article (PubMed ID: 21566453)
41. [A case of pancreatic cancer treated by gemcitabine with sequential radiotherapy].
Hisama S; Kimura M; Nishimura T; Matsushita H; Okamura S; Saitoh S; Shimokawa Y; Arakawa A; Toyama H; Tanaka Y
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1337-9. PubMed ID: 20647722
[TBL] [Abstract][Full Text] [Related]
42. [A case of locally advanced pancreatic cancer successfully resected after gemcitabine+S-1 therapy].
Moriyama M; Sawada S; Matsui K; Yoshioka I; Shibuya K; Osawa S; Yoshida T; Nagata T; Tsukada K
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2187-9. PubMed ID: 25731465
[TBL] [Abstract][Full Text] [Related]
43. Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.
Morizane C; Okusaka T; Ueno H; Kondo S; Ikeda M; Furuse J; Shinichi O; Nakachi K; Mitsunaga S; Kojima Y; Suzuki E; Ueno M; Yamaguchi T
Cancer Chemother Pharmacol; 2012 Apr; 69(4):957-64. PubMed ID: 22120961
[TBL] [Abstract][Full Text] [Related]
44. Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer.
Kawashima H; Itoh A; Ohno E; Nakamura M; Miyahara R; Ohmiya N; Hara K; Kanamori A; Itoh T; Taki T; Hirai T; Hashimoto S; Takeda K; Goto H; Hirooka Y
Cancer Chemother Pharmacol; 2011 Sep; 68(3):677-83. PubMed ID: 21132496
[TBL] [Abstract][Full Text] [Related]
45. [Effective multidisciplinary therapy mainly using S-1+ gemcitabine (GEM) for a case of pancreatic body cancer with multiple liver metastases].
Fukui H; Kou C; Fujioka M
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1727-31. PubMed ID: 23152029
[TBL] [Abstract][Full Text] [Related]
46. [A case of pancreatic neuroendocrine tumor with excessively-advanced liver metastasis treated with S-1/GEM combination chemotherapy plus the long-acting somatostatin analogue octreotide].
Yoshida Y; Sugawara N; Minami T; Iwata N; Ikeda K; Endoh T; Sasano H
Nihon Shokakibyo Gakkai Zasshi; 2013 Apr; 110(4):660-8. PubMed ID: 23558130
[TBL] [Abstract][Full Text] [Related]
47. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies.
Yanagimoto H; Ishii H; Nakai Y; Ozaka M; Ikari T; Koike K; Ueno H; Ioka T; Satoi S; Sho M; Okusaka T; Tanaka M; Shimokawa T; Kwon AH; Isayama H
J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):761-6. PubMed ID: 24925464
[TBL] [Abstract][Full Text] [Related]
48. Gemcitabine plus S-1 for metastatic pancreatic cancer.
Zhu H; Yi C; Zhao Y; Gou H
Medicine (Baltimore); 2018 Oct; 97(41):e12836. PubMed ID: 30313120
[TBL] [Abstract][Full Text] [Related]
49. [Locally advanced pancreatic cancer that enlarged after administration of gemcitabine and responded to oral TS-1--a case report].
Tanaka S; Fujii M; Goubaru M; Ohta T; Ogata M; Makino Y
Gan To Kagaku Ryoho; 2005 Oct; 32(10):1485-7. PubMed ID: 16227755
[TBL] [Abstract][Full Text] [Related]
50. [The progress of chemotherapy for advanced pancreatic cancer].
Ioka T; Katayama K; Ashida R; Takahashi H; Teshima T; Sakon M
Nihon Shokakibyo Gakkai Zasshi; 2015 Dec; 112(12):2119-26. PubMed ID: 26638783
[No Abstract] [Full Text] [Related]
51. A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma.
Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakagawa N; Takahashi S; Ohge H; Sueda T
Cancer Chemother Pharmacol; 2017 Apr; 79(4):775-781. PubMed ID: 28293715
[TBL] [Abstract][Full Text] [Related]
52. Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Li D; Chen C; Zhou Y; Chen R; Fan X; Bi Z; Li Z; Liu Y
Medicine (Baltimore); 2015 Sep; 94(35):e1345. PubMed ID: 26334891
[TBL] [Abstract][Full Text] [Related]
53. Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study.
Imaoka H; Kou T; Tanaka M; Egawa S; Mizuno N; Hijioka S; Hara K; Yazumi S; Shimizu Y; Yamao K
Eur J Cancer; 2016 Feb; 54():96-103. PubMed ID: 26741729
[TBL] [Abstract][Full Text] [Related]
54. [A case of recurrent pancreatic cancer responding to TS-1 combined gemcitabine chemotherapy after UFT combined gemcitabine chemotherapy resulting progressive disease].
Sunagozaka H; Yamashita T; Kagaya T; Kato Y; Kaneko S
Gan To Kagaku Ryoho; 2006 Jun; 33(6):829-32. PubMed ID: 16770107
[TBL] [Abstract][Full Text] [Related]
55. [Study of unresectable pancreatic cancer - successful resections after gemcitabine-based chemotherapy].
Sakuraba S; Toyoki Y; Ishido K; Kudo D; Kimura N; Wakiya T; Hakamada K
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1878-80. PubMed ID: 24393952
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study.
Zhou J; Zhao R; Wen F; Zhang P; Tang R; Du Z; He X; Zhang J; Li Q
Med Oncol; 2015 Apr; 32(4):121. PubMed ID: 25788034
[TBL] [Abstract][Full Text] [Related]
57. [A case of salvage chemotherapy with gemcitabine hydrochloride and nedaplatin for gemcitabine-refractory pancreatic cancer].
Matsuda M; Watanabe G; Hashimoto M
Gan To Kagaku Ryoho; 2008 Jan; 35(1):137-9. PubMed ID: 18195544
[TBL] [Abstract][Full Text] [Related]
58. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).
Ozaka M; Matsumura Y; Ishii H; Omuro Y; Itoi T; Mouri H; Hanada K; Kimura Y; Maetani I; Okabe Y; Tani M; Ikeda T; Hijioka S; Watanabe R; Ohoka S; Hirose Y; Suyama M; Egawa N; Sofuni A; Ikari T; Nakajima T
Cancer Chemother Pharmacol; 2012 May; 69(5):1197-204. PubMed ID: 22249272
[TBL] [Abstract][Full Text] [Related]
59. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
[TBL] [Abstract][Full Text] [Related]
60. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.
Ueno H; Okusaka T; Ikeda M; Ishiguro Y; Morizane C; Matsubara J; Furuse J; Ishii H; Nagase M; Nakachi K
Oncology; 2005; 69(5):421-7. PubMed ID: 16319514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
